Low testosterone with low or normal LH is textbook secondary hypogonadism. Here's how to read your labs, what it means, and why enclomiphene works.
The Two Types of Hypogonadism When testosterone is low, the critical question is: where is the problem? **Primary hypogonadism** — the testes themselves are failing. LH is high (pituitary is screaming for more testosterone) but the testes can't respond. Treatment: TRT. **Secondary hypogonadism** — the problem is upstream. The pituitary isn't sending enough LH/FSH signal. The testes are capable of producing testosterone but aren't being told to. Treatment: stimulate the axis from the top. The distinction is everything — because the treatment is completely different.
The classic secondary hypogonadism presentation:
|--------|----------------|
The key is the **LH/T relationship**. If T is low and LH is low-normal instead of elevated, the problem is at the hypothalamic-pituitary level, not the testes. That's secondary hypogonadism.
Common causes: sleep disruption (shift work, sleep apnea), chronic stress with elevated cortisol, obesity, opioid use, head trauma, hyperprolactinemia, or simply idiopathic age-related HPG axis blunting.
Enclomiphene is a selective estrogen receptor modulator (SERM) — specifically the trans-isomer of clomiphene, isolated because it carries all the HPG-stimulating benefit without the vision side effects associated with the cis-isomer (zuclomiphene).
**Mechanism:** Enclomiphene blocks estrogen receptors in the hypothalamus and pituitary. The brain reads this as low estrogen and responds by increasing GnRH → LH/FSH → endogenous testosterone production.
It doesn't replace testosterone. It tells your body to make more of its own.
Critical advantages over TRT:
**Dose:** 12.5–25 mg orally, 3–5 days per week
**Form:** Capsule (compounding pharmacy or research supplier)
**Monitoring:** Recheck testosterone and LH at 6 weeks
Expected response at 6 weeks with 25 mg daily:
At 6-week follow-up, track:
**Total Testosterone** — target 500–900 ng/dL for most men
**Free Testosterone** — should improve proportionally
**Estradiol (E2)** — enclomiphene raises estrogen too; if E2 climbs above 45–50 pg/mL with symptoms (water retention, sensitivity), discuss with prescriber
**LH/FSH** — both should rise, confirming the axis is responding
**Hematocrit** — unlike TRT, enclomiphene rarely raises hematocrit significantly, but monitor
**IGF-1** — interestingly, enclomiphene can modestly suppress IGF-1; if using tesamorelin concurrently, track both
Many secondary hypogonadism presentations also include suboptimal IGF-1 — often from the same underlying axis blunting (shift work, chronic stress, sleep disruption affect both axes).
Running tesamorelin (GHRH axis) concurrently with enclomiphene (HPG axis) targets two independent systems with zero competition. They work through completely different receptors and pathways.
The combined effect on body composition — testosterone restoring muscle protein synthesis and metabolic rate, IGF-1 from tesamorelin improving body fat distribution — creates an additive result that neither achieves alone.
Enter your baseline Total T, Free T, LH, FSH, Estradiol, and SHBG before starting enclomiphene. Set a 6-week draw reminder. StackAI will analyze the delta — flagging whether your LH response matches expected, whether E2 needs attention, and whether the protocol is driving you toward optimal range.
If you're not tracking labs, you're not running a protocol. You're guessing.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →